Roper Technologies to acquire CentralReach
Leading provider of SaaS solutions for Applied Behavior Analysis therapy
SARASOTA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) today announced that it has reached a definitive agreement to acquire CentralReach from Insight Partners for a net purchase price of approximately $1.65 billion, including a $200 million tax benefit resulting from the transaction. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth.
CentralReach is a leading provider of cloud-native software enabling the workflow and administration of Applied Behavior Analysis ('ABA') therapy. Over 200,000 professionals utilize CentralReach's purpose-built solutions to help provide care for individuals with autism spectrum disorder ('ASD') and related intellectual and developmental disabilities ('IDD'). ABA therapy providers rely on CentralReach's comprehensive electronic medical records platform as their mission critical operating system, which includes highly specialized tools for client set-up, practice management, claims processing, care scheduling, clinical data collection, and service delivery, along with several AI-powered add-on modules.
'CentralReach is a fantastic business with clear niche market leadership, mission critical and high ROI solutions, a high recurring revenue mix, and outstanding customer retention, which leads to strong organic revenue growth and excellent cash conversion,' said Neil Hunn, Roper's President and CEO. 'This acquisition is another example of Roper identifying a business that provides greater value creation for our shareholders. CentralReach meets each of our long-standing acquisition criteria, while also having a structurally faster organic growth profile and the ability to expand margins under Roper's long-term ownership. We are excited to welcome the CentralReach team to the Roper family and look forward to partnering with the team to execute their strategy.'
Acquisition financial outlook and financing
CentralReach is expected to contribute approximately $175 million of revenue and $75 million of EBITDA for the twelve months ending June 30, 2026, and will be reported in Roper's Application Software segment. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth.
The transaction is expected to close in April/May 2025, subject to regulatory approval and customary closing conditions, and will be funded using Roper's revolving credit facility. Additional information about CentralReach is available in the Investors section of Roper's website (www.ropertech.com).Roper supplements its consolidated financial statements presented on a GAAP basis with certain non-GAAP financial information, including EBITDA, to provide investors with greater insight, increase transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Roper defines EBITDA as earnings before interest, taxes, depreciation, and amortization. Roper has not provided a reconciliation of the expected EBITDA contribution by CentralReach to the expected net income contribution by CentralReach for the twelve months ending June 30, 2026 because we are unable to quantify certain amounts that would be required to be included in CentralReach's contribution to net income without unreasonable efforts. In addition, Roper believes such reconciliation would imply a degree of precision that would be confusing or misleading to investors. The non-GAAP financial measure disclosed by Roper in this press release should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP, and the financial results prepared in accordance with GAAP and reconciliations from these results should be carefully evaluated.
About Roper Technologies
Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company's website at www.ropertech.com.
About CentralReach
CentralReach is a leading provider of Autism and IDD Care Software, providing a complete, end-to-end software and services platform that helps therapists who serve children and adults diagnosed with autism spectrum disorder (ASD) and related intellectual and developmental disabilities (IDD). With its roots in Applied Behavior Analysis, the company is revolutionizing how the lifelong journey of autism and IDD care is enabled at home, school, and work with powerful and intuitive solutions purpose-built for each care setting.
Trusted by more than 200,000 professionals globally, CentralReach is committed to ongoing product advancement, market-leading industry expertise, world-class client satisfaction, and support of the autism and IDD community to propel autism and IDD care into a new era of excellence. For more information, please visit www.CentralReach.com.
Contact information: Investor Relations941-556-2601 investor-relations@ropertech.com
The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should," "will," "believes," "intends" and similar words and phrases. These statements reflect management's current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, acquired businesses, including obtaining any required regulatory approvals with respect thereto. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, including risks related to labor shortages and rising interest rates, changes in foreign exchange rates, risks related to changing U.S. and foreign trade policies, including increased trade restrictions or tariffs, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises (such as the COVID-19 pandemic) or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, including as a result of inflation and potential supply chain constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
2 Growth Stocks to Stash and 1 to Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Yahoo
39 minutes ago
- Yahoo
Basecamp Research Announces Breakthrough Discovery of Over One Million New Species, Yielding Enormous New Database Purpose-Built for Generative Foundation Models in Biology
Head to Head Comparison 10X Tree of Life Basecamp Research_Cameroon Basecamp Research_CostaRica Uncharted Diversity Kmer Umap DNA Basecamp Research_Malta Company's multi-year biodiscovery programme, driven by strategic economic partnerships across 26 countries, has resulted in BaseDataTM the largest and fastest growing database of new biological protein sequences - 9.8 billion - ever built New species data gives scientists new potential therapeutic solutions to areas including antimicrobial resistance, gene editing, and environmental sustainability Scientific preprint demonstrates how BaseData breaks through biology's data wall and now exceeds the size, growth and diversity of public datasets that serve as the foundations for AI applications in the life sciences industry LONDON and CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Basecamp Research, an AI company dedicated to using nature to solve the most pressing challenges in the life sciences, today announced the discovery of over 1 million new species as part of BaseDataTM, the world's largest biological protein sequence database, and the first to be purpose-built to power the next era of generative biology. 'The rise of generative biology – using AI foundation models to design, generate, and annotate proteins, pathways and therapeutics – creates unprecedented demand for large, diverse biological sequence databases,' said Glen Gowers, Ph.D., CEO and Co-Founder of Basecamp Research. 'The million plus new species we've identified to date gives us an unrivaled understanding of how life on Earth has evolved over billions of years. We believe it will help the life sciences sector overcome today's critical data bottleneck and build a truly generative biology ecosystem with applications across nearly every area of human and planetary health.' Today, research relies heavily on public, open access biological sequence databases. Designed originally as academic collaboration tools, these databases are accessed over 100 million times per day and are the source of over 50% of all life science patents. This usage has grown by 10x in the last decade and continues to accelerate thanks in large part to the increasing use of data-hungry AI models in biopharma research. However, compared to all life on Earth, these databases are incomplete, riddled with redundancies, and highly-biased – 70% of all sequence data comes from just 10 species. Furthermore, the information in these databases is growing slowly, and companies using these databases for commercial purposes face increasing scrutiny on various legal fronts. This lack of growth and diversity holds back model performance and is a fundamental problem that slows research advancements in the life sciences: the data wall. Basecamp Research has broken through this data wall by pioneering an economic partnership-based model that incentivises the collection of samples across the planet's most extreme and biodiverse environments, working with 125+ communities in 26 countries. In a milestone disclosure, the company is unveiling the results of its biodiscovery initiative — BaseData has identified 9.8 billion new protein sequences. Once redundant sequences are removed, BaseData is currently over 10x bigger than all public databases combined. It continues to grow rapidly, offering a fundamentally new understanding of life on Earth. 'Biological foundation models are the key to continued progress in the life sciences, but their growth is slowing and performance is suffering,' said Oliver Vince, Ph.D., Co-Founder of Basecamp Research. 'It's this data wall that discourages life science teams in building and using huge biological foundation models. At Basecamp, we've demonstrated a new, scalable economic framework for expanding our knowledge of life on Earth and we show it is possible to overcome the data wall that's limiting progress for others in bioAI. Training our own foundation models on this data is enabling collaborations across the life sciences sector to help solve pressing challenges in drug discovery.' Basecamp Research scientists have uncovered more than one million new microbial species to date in some of the planet's most remote and extreme environments, expanding the view of the tree of life by over 10 times. The previously hidden biological insights in this data, combined with foundational AI models, will help shape everything from environmental sustainability and repair to therapeutics development. Examples of such newly discovered species include: On a World War II shipwreck, a new species of Burkholderia, a type of bacteria known for its ability to remove heavy metals from the environment. This could help improve pollution control and deepen our understanding of how bacteria resist antibiotics. In acidic hot springs near an active volcano, a new member of the Sulfolobaceae family that thrives in searing temperatures. Its specialized proteins, stress-response systems and stability near boiling point could help develop new ways to deliver medicine or preserve biological materials under harsh conditions. In Antarctic soil, a new species of Candidatus Eremiobacterota, a bacterium that survives by drawing nourishment from the air, generating its own water using hydrogen as an energy source — a finding that could inform novel gas-based drug delivery systems or therapeutic approaches. Basecamp Research is sharing further details in a pre-print paper and plans to offer early access to its unique data to life sciences researchers who express interest via its website to help them further their research. About Basecamp ResearchBasecamp Research is solving the most pressing challenges in the life sciences by exploring Beyond Known BiologyTM. We build foundational AI models on top of the world's largest, ethically-sourced database of biological information to give AI the most complete understanding of biology ever. This allows us to design more complex biological systems with performance improving dramatically as AI sees more diversity and context. Basecamp Research collaborates with biopharma companies and academic research institutions to design novel protein sequences and biological systems that can transform therapeutic research and development. Our team of explorers, scientists and policy experts proudly work with more than 100 biodiversity partners across the globe, allowing us to deliver breakthroughs that can have a profound impact on healthcare and the lives of patients. Fast Company named Basecamp Research one of biotech's top 10 Most Innovative Companies in 2025. For more information, visit BaseDataTM and Beyond Known BiologyTM are brand names and technologies of Basecamp Research. Media Contact:Adam SilversteinSCIENT PRadam@ Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities
SOMERSET, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, a global leader in the comparator sourcing and clinical trial supplies, has launched NCE Grid, the world's first free NCE-1 intelligence platform - built to decode, centralize, and visualize Para IV and NCE-1 opportunities in real-time. Until now, tracking NCE exclusivity expirations and Paragraph IV filings has been a fragmented, manual, and cumbersome process, lacking a centralized solution. Regulatory updates are scattered across various portals, intelligence is buried in siloed databases, and timelines are tracked using spreadsheets. The result? Competitive blind spots, misaligned R&D, and a race already lost before it begins. For generic pharmaceutical companies aiming to be the 'first to file,' intelligence gaps, scattered data, and missed timelines can result in lost exclusivity and millions in revenue. NCE Grid changes Grid is the world's first free tool to integrate every critical data point, including molecule, innovator name, NCE-1 date, revenue, therapeutic usage, expected sales growth, and CAGR% into one intuitive platform. With real-time visualizations and actionable insights, NCE Grid empowers strategy, regulatory, and portfolio teams to identify, prioritize, and act on first-to-file opportunities with clarity and speed. 'We created NCE Grid because we saw too many companies struggle with fragmented insights and missed opportunities,' said Salim Shaikh, Founder and CEO of Spring Bio Solution. 'In a race where timing is everything, our platform brings clarity, speed, and a competitive edge to decision-makers. When you think Para IV, think NCE Grid — Your trusted guide for strategic drug development.' To learn more, visit About Spring Bio Solution Spring Bio Solution partners with CROs, pharmaceutical companies, and research institutions worldwide, offering reliable solutions for comparator sourcing and clinical trial supplies. With offices and WDL (wholesale Drug Distribution License) facilities across the USA, EU, Singapore, and India, and a robust network of 400+ distribution partners and 30+ innovators, Spring Bio Solution ensures timely and compliant access to critical drug supplies. Trusted by over 600 clients and maintaining a 99.9% success rate for sourcing comparator drugs/ RLDs/ innovator samples, the company offers industry-leading cold chain capabilities, ranging from -60°C to ambient temperatures. Through its partnership with LSPedia, Spring Bio Solution also ensures full DSCSA compliance and end-to-end traceability. With experience supporting over 1,000 clinical trials and more than 12,000 bioequivalence studies, Spring Bio Solution empowers sponsors to de-risk operations and accelerate drug development with confidence. For media inquiries, please contact: Navdeep TrivediVice President & Head, Digital MarketingSpring Bio in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
